Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 4.87 USD -3.37% Market Closed
Market Cap: $35.1m

Wall Street
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 9.52 USD with a low forecast of 4.04 USD and a high forecast of 18.9 USD.

Lowest
Price Target
4.04 USD
17% Downside
Average
Price Target
9.52 USD
95% Upside
Highest
Price Target
18.9 USD
288% Upside
Atara Biotherapeutics Inc Competitors:
Price Targets
ACIU
AC Immune SA
201% Upside
LAND
Gladstone Land Corp
0% Upside
MRVL
Marvell Technology Group Ltd
59% Upside
KRNY
Kearny Financial Corp
11% Upside

Revenue
Forecast

N/A
Past Growth
-10% / Year
Estimated Growth
Estimates Accuracy
-41%
Average Miss
N/A
Past Growth
-10% / Year
Estimated Growth
Estimates Accuracy
-41%
Average Miss

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 4 years is -10%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-72%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-72%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATRA's stock price target?
Price Target
9.52 USD

According to Wall Street analysts, the average 1-year price target for ATRA is 9.52 USD with a low forecast of 4.04 USD and a high forecast of 18.9 USD.

What is Atara Biotherapeutics Inc's Revenue forecast?
Projected CAGR
-10%

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 4 years is -10%.

Back to Top